Abstract
Up to now most of the cells used in cell therapeutics have been mesenchymal stem cells (MSCs). However, mononuclear cells (MNCs) from cord blood (CB) or G-CSF (granulocyte-colony stimulating factor)-mobilized peripheral blood (mPB) MNCs could be an alternative option because MNCs contain both HSCs (hematopoietic stem cells) and MSCs. In addition, cellular components other than purified HSCs or MSCs could play important roles in tissue regeneration. The optimal route of administration in cell therapy is another important issue. The therapeutic benefits and clinical availability of intravenous infusion of CB- or mPB-MNCs in the field of cell therapy will be briefly reviewed.
Highlights
Cell therapy has emerged as an advanced medical technology for restoring damaged tissues and organs
mesenchymal stem cells (MSCs): Mesenchymal Stem Cells; mononuclear cells (MNCs): Mononuclear Cells; MI: Myocardial Infarction; bone marrow (BM): Bone Marrow my colleagues compared levels of inflammatory cytokines and neurotrophic factors in PB-MNCs and mobilized peripheral blood (mPB)-MNCs from children with cerebral palsy (CP) with those from healthy adult donors and from cord blood (CB)-MNCs donated from healthy newborns
We proposed that the different levels of neurotrophic factors and anti-inflammatory cytokines in the mPBMNCs of CP children and the CB-MNCs of healthy children suggested that these cells had potential as new sources for cellular therapy for individuals with neurologic diseases
Summary
Cell therapy has emerged as an advanced medical technology for restoring damaged tissues and organs. There have recently appeared clinical reports demonstrating the therapeutic potential of autologous BM- or mPB-MNC transplantation in patients with limb ischemia or myocardial infarction.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
